Abstract
4534 Background: pts with either CDDP refractory (REF) or with a poor prognosis relapse (REL) GCT, defined as progressing less than 2 or between 2 and 6 months (mos) of CDDP administration respectively have dismal prognosis.Px induces 11 to 26% response rates (RR) in a similar pt population.Ox is a platinum compound with a lack of cross resistance with CDDP. Methods: REF and REL pts, who had received at least one line of CT containing Etoposide+CDDP. Treatment: combination of Px (175 mg/m2, 3h infusion) followed by Ox (130 mg/m2, 2h infusion) administered q3 weeks. Endpoints were RR (WHO criteria) and tumor marker decrease (TMD)>90% or >50%.The 2-step modified Gehan design was used for sample size determination. Results: 26 pts were enrolled; median age 31 yrs (range 18–46); PS 0/1:13/13; 18 had non seminoma (among whom 5 mediastinal primaries), 2 seminoma and 6 mixed GCT; 16 pts were REF and 10 pts were REL; 22, 3 and one pts had previously received 2, 3 and 5 lines of CDDP based CT. A total of 87 cycles (median 4,range 1 to 7) were administered. The worst toxicity (NCI-CTC) consisted in: grade (G) 3 and 4 neutropenia (N) in 3 and 4 pts respectively, G 3 anemia in 3 pts, G 3 thrombocytopenia in one pt, G 3 neuropathy in one pt and G3 infection without N in one pt. One Partial Response with normal TM (lasting 18+ mos) and 4 TMD > 90% and 3 TMD > 50% were observed. Median Time to Tumor Progression and Overall Survival (months) were 2.0 [95% CI :1.5 - 2.5] and 8.8 [95% CI : 5 -12] respectively. However 2 pts were eventually salvaged by surgical exeresis of limited disease and are alive free of disease progression at 13+ and 23+ months respectively. Conclusions: Ox-Px Combination is safe and looks active in refractory and relapsed GCT, it warrants further developments within the treatment strategy in these patients. No significant financial relationships to disclose.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have